The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

(2010) Jieru Meng et al.   CANCER BIOLOGY & THERAPY

Endogenous LKB1 knockdown accelerates G1/S transition through p53 and p16 pathways

(2010) Xiaoyan Liang et al.   CANCER BIOLOGY & THERAPY

Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine

(2010) Laura W. Goff et al.   INVESTIGATIONAL NEW DRUGS

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects

(2009) Alla V Ivanova et al.   Molecular Cancer

LKB1 and Lung Cancer: More Than the Usual Suspects

(2008) U. Shah et al.   CANCER RESEARCH

Loss and Reduction of Fus1 Protein Expression is a Frequent Phenomenon in the Pathogenesis of Lung Cancer

(2008) L. Prudkin et al.   CLINICAL CANCER RESEARCH

Tumor Suppressor FUS1 Signaling Pathway

(2008) Lin Ji et al.   Journal of Thoracic Oncology